Study of SGR-1505 in Mature B-Cell Neoplasms

Study Number
3589423
Phase
I
Age Group
Adult
Principal Investigator
Francisco Hernandez-Ilizaliturri
Purpose

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Check your eligibility for this trial
Check now
Full Title

A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE
ESCALATION STUDY OF SGR-1505 AS
MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL
MALIGNANCIES

ClinicalTrials.Gov ID
NCT05544019

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.